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Left ventricular (LV) systolic function in hypertrophic cardiomy-
opathy (HCM) is usually normal. Late in the disease, however,
LV systolic dysfunction and dilatation are recognized. Although
abnormalities in cardiac sympathetic nerve activity in patients
with HCM have been demonstrated using 123I-metaiodobenzyl-
guanidine (MIBG) myocardial scintigraphy, the changes of car-
diac sympathetic nerve activity throughout the clinical course
from typical to end-stage HCM are unclear. The objective of this
study was to evaluate the relationship between abnormalities on
123I-MIBG myocardial scintigraphy and pathophysiologic
changes in patients with HCM. Methods: We performed 123I-
MIBG scintigraphy on 46 patients with HCM and 18 age-
matched control subjects. The patients were categorized into 3
groups: 28 patients with normal LV systolic function (group A), 9
patients with LV systolic dysfunction (group B), and 9 patients
with LV systolic dysfunction and dilatation (group C). With pla-
nar 123I-MIBG imaging, the heart-to-mediastinum ratio for early
and delayed acquisitions and the washout rate were calculated.
With SPECT, polar maps of the LV myocardium were divided
into 20 segments. The regional uptake and washout rate were
calculated from semiquantitative 20-segment bull’s-eye analy-
sis. Results: The early uptake was significantly lower in group C
than in the control group (P  0.01). The washout rate was pro-
gressively higher in group A, group B, and group C (P  0.01).
Reduced regional early uptake was found in 2.9 3.4 (group A),
4.1  4.7 (group B), and 7.4  4.3 (group C) segments, respec-
tively. In group C, regional early uptake was significantly re-
duced, predominantly in the interventricular septal wall, and
regional washout rate was increased in the apex and lateral wall.
Conclusion: These results suggest that cardiac sympathetic
nerve abnormalities in patients with HCM may advance with
development of LV systolic dysfunction and dilatation and that
123I-MIBG myocardial scintigraphy may be a useful tool for the
evaluation of pathophysiologic changes in HCM.
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Hypertrophic cardiomyopathy (HCM) is a disease char-
acterized by disproportionate left ventricular (LV) hypertro-
phy and LV diastolic dysfunction. LV systolic function in
HCM is usually normal or supernormal (1). The clinical
course and prognosis in patients with HCM are character-
ized by sudden death associated with life-threatening ar-
rhythmias, by LV diastolic dysfunction, and by stroke as-
sociated with atrial fibrillation (2). Late in the disease,
however, impaired LV systolic function and LV dilatation
are recognized in some patients with HCM (2,3). Conse-
quently, these patients whose disease has evolved into the
end stage are at high risk of progressive congestive heart
failure (2,3). Nevertheless, the characteristics of end-stage
HCM have been studied only rarely.
Cardiac nerve activity plays an important role in the
modifications of cardiac function that contribute to such
disease processes as heart failure (4). Recently, 123I-me-
taiodobenzylguanidine (MIBG), an analog of norepineph-
rine, has been used to evaluate cardiac sympathetic nerve
activity in various kinds of pathologic conditions (5–8).
HCM is reported to involve dysfunctional sympathetic in-
nervation (9,10). However, the changes in cardiac sympa-
thetic nerve activity throughout the clinical course from
typical to end-stage HCM are unclear. The present study
was performed to evaluate the relationship between abnor-
malities on 123I-MIBG myocardial scintigraphy and patho-
physiologic changes in patients with HCM so that the clin-
ical course of and mechanisms leading to LV systolic
dysfunction and dilatation can be further understood.
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MATERIALS AND METHODS
Patients with HCM
Before the study, informed consent was obtained from all sub-
jects. The study included 46 patients with HCM (30 male and 16
female; mean age, 52.7  13.1 y). The diagnosis of HCM was
based on the typical clinical findings of unexplained cardiac hy-
pertrophy and a maximum LV wall thickness (WT)  13 mm at
some time during the clinical course (11). LV systolic dysfunction
was defined as LV fractional shortening (FS)  25%, and LV
dilatation was defined as LV end-diastolic dimension (EDD)  55
mm on echocardiography. At the time of the 123I-MIBG scinti-
graphic study, the patients with HCM were categorized into 3
groups: group A, with normal LV systolic function (n 28; WT
13 mm, FS  25%, and EDD  55 mm); group B, with LV
systolic dysfunction (n  9; WT  13 mm, FS  25%, and
EDD  55 mm); and group C, with LV systolic dysfunction and
dilatation (n  9; WT  13 mm, FS  25%, and EDD  55 mm).
Although the WT in 1 patient in group B and 3 patients in group
C was 13 mm, they were also enrolled in the study because they
had a family history of HCM and the same gene mutation as the
proband with HCM. Patients with myocardial infarction, valvular
heart disease, hypertension, or diabetes mellitus were excluded
from the study.
Control Subjects
As a control group, 18 subjects with no evidence of heart
disease possibly affecting sympathetic nervous activity were in-
vestigated. There were 7 men and 11 women ranging in age from
27 to 74 y (mean age, 52.9  15.4 y).
Evaluation of Cardiac Sympathetic Nerve Activity
No subjects were taking reserpine or tricyclic antidepressants at
the time of the study. The method of 123I-MIBG scintigraphy has
been published previously (12,13). In brief, each subject was
administered an intravenous injection of 120–140 MBq of com-
mercially available 123I-MIBG between 9:00 and 10:00 AM. A
5-min static acquisition was made in the anterior view at 20 min
(early) and 3 h (delayed) after the injection of 123I-MIBG. Projec-
tion images were acquired after each static acquisition with a
3-head scintillation camera (model 9300A; Toshiba) equipped
with parallel-hole, high-resolution collimators. The energy dis-
crimination was centered on 159 keV with a 20% window. Sixty
projection images were obtained in a 64  64 matrix over a 360°
arc with 30-s acquisitions for each view. Tomographic images
were reconstructed using a Butterworth filter with a cutoff fre-
quency of 0.47 cycle/cm and an order of 8.
Three nuclear medicine experts who were unaware of other
clinical findings analyzed the data by consensus. On the anterior
planar 123I-MIBG images, the rectangular region of interest (ROI)
was manually drawn over the whole heart, including LV cavity, on
the upper mediastinum. The heart-to-mediastinum ratios for the
early and delayed images were calculated to quantify cardiac
123I-MIBG uptake as a fraction of the mean count per pixel in the
heart ROI divided by that in the upper mediastinum ROI. The
washout rate was calculated as follows: washout rate  (Ec –
Dc)  100/Ec, where Ec is early cardiac count density and Dc is
decay-corrected delayed cardiac count density.
We evaluated nongated 123I-MIBG images using Quantitative
Gated SPECT software (version 2; Cedars-Sinai Medical Center)
(14). The regional uptake and washout rate were calculated using
semiquantitative 20-segment bull’s-eye analysis, which has been
previously described (12,13). In brief, polar maps of all subjects
were divided into 20 segments as shown in Figure 1. The rectan-
gular ROI was placed on each of the 20 segments. The percentage
uptake in the early image and the washout rate in each segment
were obtained. An abnormal reduction in regional 123I-MIBG
uptake was defined as uptake that was 2 SDs less than the mean
value of the same segment in the control group.
Echocardiography
All patients underwent echocardiography by experienced oper-
ators within 1 wk of the 123I-MIBG myocardial scintigraphy.
Measurements of LV dimensions, the thickness of the interven-
tricular septum, and the thickness of the LV posterior wall were
taken at the level of the tips of the mitral valve leaflets in the
parasternal long-axis view. The FS was calculated as the difference
in end-diastolic and end-systolic dimensions divided by the EDD.
Statistical Analysis
Continuous data are presented as mean  SD, and categoric
data are presented as relative frequency (percentage). For semi-
quantitative analysis of 123I-MIBG scans, each of the 20 segments
of the polar map was compared with the corresponding segment in
the control group. Paired mean values were compared using 1-way
ANOVA followed by the Scheffe´ multiple-comparisons test. Cat-
egoric data were compared using the 2 test. P  0.05 was
considered statistically significant.
RESULTS
Baseline Characteristics of Study Patients
The baseline clinical characteristics of the patients are
summarized in Table 1. No significant differences in sex or
age existed among the 3 groups. New York Heart Associ-
ation functional class was significantly and progressively
higher in group A, group B, and group C. Echocardiography
showed that interventricular septal thickness and maximum
LV WT were significantly thinner, LV EDD and LV end-
FIGURE 1. Polar map of LV myocardium was divided into 20
segments as shown, and uptake and washout rate in each
section were determined.
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systolic dimensions were significantly larger, and LV FS
was significantly lower in group C than in either group A or
group B. The other echocardiographic parameters were
comparable across groups.
123I-MIBG Scintigraphic Data
123I-MIBG scintigraphic data are summarized in Table 2.
Regarding global 123I-MIBG parameters, the early and de-
layed uptake ratios for the heart and mediastinum were
significantly lower in group C than in the control group.
Washout rate was significantly and progressively higher in
the control group, group A, group B, and group C, as shown
in Figure 2.
Regarding regional 123I-MIBG parameters, the number of
segments with reduced early uptake was significantly
greater in group C than in group A (P  0.01). The number
of segments with an increased washout rate tended to in-
crease progressively in group A, group B, and group C, but
the increases were not statistically significant.
Compared with the corresponding segments in the control
group, no segments in group A showed significantly re-
duced regional early uptake, and only a few segments at-
tained significance in group B. In contrast, regional early
uptake was significantly reduced in the interventricular sep-
tal wall, predominantly in group C (Fig. 3). In addition, the
regional washout rate in group C was significantly increased
in the apex and lateral wall, whereas in group A this factor
was not significantly increased in any of the segments
(Fig. 4).
DISCUSSION
HCM is a primary myocardial disease with a wide clin-
ical spectrum and marked variability in pathophysiology.
Although recent studies provide evidence of abnormal car-
diac autonomic innervation in patients with HCM (6,13–
16), we are aware of no published reports that describe the
changes of cardiac sympathetic nerve activity—in particu-
TABLE 1
Baseline Characteristics of Patients with HCM
Characteristic Group A Group B Group C P
Patients (n) 28 9 9
Male patients (n) 20 (71%) 5 (56%) 5 (56%) 0.2539
Age (y) 48.8  14.0 56.8  9.5 60.7  8.5 0.6560
Patients in NYHA class III/IV (n) 1 (4%) 4 (44%) 7 (78%) 0.001
Echocardiography findings
IVST (mm) 18.4  3.4 13.9  5.6 11.2  3.3 0.001
PWT (mm) 12.3  2.8 12.3  2.5 10.4  0.9 0.1483
MWT (mm) 18.7  3.5 15.1  4.3 12.2  2.1 0.001
LAD (mm) 39.1  6.0 44.0  9.1 44.8  9.6 0.7110
EDD (mm) 44.8  4.9 49.4  5.0 60.3  5.5 0.001
ESD (mm) 25.7  5.0 37.6  3.3 51.6  6.0 0.001
FS (%) 42.8  8.8 23.9  4.3 14.7  3.9 0.001
Patients receiving -blocker (n) 6 (21%) 1 (11%) 3 (33%) 0.5194
NYHA  New York Heart Association; IVST  interventricular septal thickness; PWT  LV posterior wall thickness; MWT  maximum
LV wall thickness; LAD  left atrial dimension; ESD  LV end-systolic dimension.
TABLE 2
123I-MIBG Scintigraphic Data
Parameter Control (n  18)
HCM
Group A (n  28) Group B (n  9) Group C (n  9)
Early H/M 2.09  0.19 1.92  0.25 1.93  0.45 1.70  0.24*
Delayed H/M 2.19  0.26 1.87  0.25 1.71  0.33* 1.49  0.26*†
WR 0.10  0.06 0.18  0.05* 0.23  0.09* 0.30  0.04*†
Regional EU (n) — 2.93  3.40 4.11  4.68 7.44  4.28†
Regional WR (n) — 3.14  4.16 5.11  6.51 7.11  6.09
*P  0.05 vs. control.
†P  0.05 vs. HCM with normal LV systolic function.
H/M  heart-to-mediastinum uptake ratio; WR  washout rate; regional EU  number of segments with significantly reduced early
123I-MIBG uptake compared with control group; regional WR  number of segments with significantly increased 123I-MIBG washout rate
compared with control group.
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lar, regions of damage—throughout the clinical course from
typical to end-stage HCM. We reported previously that the
heterogeneity of cardiac sympathetic nerve activity corre-
lated with cardiac function in patients with HCM (14). In
the current study, we evaluated in more detail the relation-
ship between abnormalities on 123I-MIBG myocardial scin-
tigraphy and the pathophysiologic changes in patients with
HCM. The major findings of the study were, first, that
cardiac sympathetic denervation measured by the early up-
take of 123I-MIBG is vague or nonexistent in HCM patients
with normal LV systolic function but eventually occurred in
the end stage characterized by LV systolic dysfunction and
dilatation; second, that cardiac sympathetic nerve hyperac-
tivity measured by washout rate had already occurred in the
stage of normal LV systolic function in HCM and increased
with the progression to the end stage; and third, that espe-
cially in end-stage HCM, regional sympathetic denervation
was shown predominantly in the interventricular septal
wall, as well as in the apex and the anterior and posterior
walls. In contrast, regional sympathetic nerve hyperactivity
was recognized in the apex and apical lateral wall.
These findings might be related to histopathologic
changes in HCM. HCM is a disease caused by a mutation in
the genes encoding sarcomere proteins such as -myosin
heavy chain, cardiac troponin T, and cardiac troponin I
(17–19). Mutated proteins and the myocyte disarray char-
acterizing HCM may decrease the function of the myocar-
dial contractile unit. In response to this dysfunction, sym-
pathetic nerve activity may be increased and thus may lead
to myocyte hypertrophy resulting in normal systolic func-
tion of the global left ventricle. Considering these mecha-
nisms, in the patients of group A, with normal LV systolic
function, early uptake of 123I-MIBG might not differ from
the values in control subjects, and the washout rate of
123I-MIBG might be increased in comparison with control
values.
In contrast to the histopathologic changes in HCM, de-
velopment of LV systolic dysfunction during the transition
FIGURE 2. Early uptake ratio and wash-
out rate of 123I-MIBG in control group and
in groups of patients with HCM.
FIGURE 3. Polar maps depicting differ-
ences in relative 123I-MIBG early uptake be-
tween groups of patients with HCM. Ant 
anterior wall; Lat  lateral wall; Post 
posterior wall; Sept  interventricular sep-
tum.
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from typical HCM with wall hypertrophy to end-stage HCM
is related to thinning of the interventricular septal wall (20).
Histopathologic examinations revealed extensive myocar-
dial fibrosis in the thin septal wall of the end-stage HCM
heart (21). These findings led us to hypothesize that devel-
opment of LV systolic dysfunction caused by myocyte
death and increased fibrosis in the septal wall leads to an
increase in sympathetic nerve activity resulting in a further
increase in washout of 123I-MIBG. When these histopatho-
logic changes progress, few myocytes and extensive fibrosis
exist in the septal wall, and LV systolic dysfunction and
dilatation develop. Consequently, early uptake of 123I-
MIBG is decreased in the septal wall. In response to de-
creased cardiac function, sympathetic nerve activity in the
apex and lateral wall, where myocytes are viable, increases,
thus preserving LV function. Our hypothesis may account
for the indications that early uptake of 123I-MIBG was
decreased in the septal wall and that the washout rate of
123I-MIBG was increased in the apex and lateral wall in
group C, with LV systolic dysfunction and dilatation.
However, we acknowledge that the small sample size
limits our study. We recognize that to include a larger
number of patients in future studies would be optimal.
However, the current data are important in determining the
possible role cardiac sympathetic nerve activity plays in
evaluating pathophysiologic changes in HCM.
In this study, we investigated HCM by using regional
parameters in addition to global parameters for a more
accurate comparison. There were a few discrepancies be-
tween the results of global and regional parameters such that
no segment of increased washout rate was found in group A.
One possible reason for this finding may be heterogeneous
sympathetic nerve activity based on heterogeneous wall
hypertrophy in HCM. Because global parameters have lim-
itations due to lung overlap, evaluation of regional washout
rate might provide more accurate information than evalua-
tion of global washout rate. On the other hand, regional
early uptake is relative to percentage uptake. If there are
regions of increased uptake, one may erroneously conclude
that decreased uptake is present in a region that actually has
normal uptake. If new technology for the assessment of
absolute regional uptake is developed, more accurate infor-
mation will be available.
Several metabolic nuclear imaging studies have demon-
strated evidence of myocardial ischemia in patients with
HCM (22–24). In addition, increased WT in intramyocar-
dial coronary arteries is found in the interventricular septum
in patients with end-stage HCM (21,25). Because cardiac
sympathetic nerves are more sensitive to ischemia than are
myocytes (26,27), myocardial ischemia may also play an
important role in the changes in regional cardiac sympa-
thetic nerve activity in HCM. However, the methods of the
present study could not discriminate between the influence
of ischemia and the influence of pathologic changes on
cardiac sympathetic nerve function in HCM. For that pur-
pose, other assessments, such as the combination of 123I-
MIBG and sestamibi myocardial scintigraphies, may be
useful.
HCM is the most common cause of cardiac-related sud-
den death in people younger than 30 y (28). However, a
recent report on natural history indicates that progression of
HCM to LV dilatation and dysfunction occurs in 10%–15%
of patients (2,3,29). In addition, Seiler et al. found that
patients with LV dilatation have a worse prognosis than
those without, particularly regarding quality of life (30). We
expect that our results will improve understanding of the
process to end-stage HCM and be useful in the management
of patients with HCM.
CONCLUSION
The results from our study suggest that abnormalities of
cardiac sympathetic nerve activity in patients with HCM
may advance with the development of LV systolic dysfunc-
tion and dilatation and that 123I-MIBG myocardial scintig-
raphy may be a useful tool for evaluating pathophysiologic
changes in HCM.
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